Plain-English translation of NCT06849193 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is collecting detailed health and tumor information from patients with unresectable bile duct cancer who are receiving chemotherapy combined with immunotherapy. Researchers want to use this information to build a prediction model that can help doctors identify which patients are most likely to benefit safely from this combined treatment approach. By understanding patterns in blood tests, imaging, tumor characteristics, and overall health, doctors hope to personalize treatment decisions for future patients.
Bile duct cancer is difficult to treat and not all patients respond equally well to chemotherapy combined with immunotherapy. Some patients may face higher risks from these treatments due to their individual health situation. This study aims to create a tool that helps doctors predict which patients will tolerate and benefit from this treatment, and which patients may need extra care or a different approach.
You likely qualify if…
You likely don't qualify if…
This is an observational study, meaning you will receive your standard chemotherapy and immunotherapy treatment as planned by your doctor. Researchers will collect information from your medical visits, including blood tests, imaging scans, and measurements of how you are doing overall. They will track this information over time to understand how patients respond to treatment and which factors help predict outcomes. You will not receive any experimental medication through this study; instead, your existing medical data will help build a tool for future patients.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
China